Ascelia Pharma
Develops novel drugs for rare oncology, including an oral MRI contrast agent for cancer patients.
ACE | ST
Overview
Corporate Details
- ISIN(s):
- SE0010573113 (+2 more)
- LEI:
- 5493002YR9VCJJPWYN08
- Country:
- Sweden
- Address:
- Hyllie Boulevard 34, 215 32 Malmö
- Website:
- https://www.ascelia.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Ascelia Pharma is a biotechnology company focused on developing and commercializing novel drugs for rare oncology conditions, addressing unmet medical needs. The company's lead drug candidate, Orviglance®, is a novel, non-gadolinium-based oral contrast agent for magnetic resonance imaging (MRI). It is designed to improve the detection and visualization of liver metastases, particularly for cancer patients with severely impaired kidney function who cannot use existing gadolinium-based agents. Ascelia Pharma is advancing its pipeline through late-stage clinical development and the regulatory submission process, including a New Drug Application (NDA) to the U.S. Food and Drug Administration for Orviglance®.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-23 12:16 |
Major Shareholding Notification
|
Swedish | 10.9 KB | ||
| 2025-09-30 07:30 |
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Ascelia Pharma AB
|
Swedish | 191.1 KB | ||
| 2025-09-30 07:30 |
Declaration of Voting Results & Voting Rights Announcements
Change in Number of Shares and Votes in Ascelia Pharma AB
|
English | 190.0 KB | ||
| 2025-09-24 13:22 |
Major Shareholding Notification
|
Swedish | 11.1 KB | ||
| 2025-09-22 20:55 |
Share Issue/Capital Change
Ascelia Pharma har genomfört en riktad nyemission om cirka 30 MSEK
|
Swedish | 204.3 KB | ||
| 2025-09-22 20:55 |
Share Issue/Capital Change
Ascelia Pharma Has Completed a Directed Share Issue of Approximately SEK 30 Mil…
|
English | 203.5 KB | ||
| 2025-09-22 17:36 |
Share Issue/Capital Change
Ascelia Pharma avser att genomföra en riktad nyemission av aktier om cirka 30 M…
|
Swedish | 203.7 KB | ||
| 2025-09-22 17:36 |
Share Issue/Capital Change
Ascelia Pharma Intends to Carry Out a Directed Share Issue of Approximately SEK…
|
English | 202.8 KB | ||
| 2025-09-02 16:10 |
Share Issue/Capital Change
Fenja Capital II A/S påkallar konvertering av samtliga utestående konvertibler …
|
Swedish | 190.4 KB | ||
| 2025-09-02 16:10 |
Share Issue/Capital Change
Fenja Capital II A/S Requests Conversion of All Outstanding Convertibles for a …
|
English | 190.1 KB | ||
| 2025-08-21 07:30 |
Interim Report
|
Swedish | 4.5 MB | ||
| 2025-08-21 07:30 |
Interim Report
|
English | 4.4 MB | ||
| 2025-05-16 07:30 |
Interim Report
|
Swedish | 4.4 MB | ||
| 2025-05-16 07:30 |
Investor Presentation
|
English | 4.4 MB | ||
| 2025-05-07 16:30 |
Post-Annual General Meeting Information
Kommuniké från årsstämma den 7 maj 2025 i Ascelia Pharma AB
|
Swedish | 193.2 KB |
Automate Your Workflow. Get a real-time feed of all Ascelia Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Ascelia Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Ascelia Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-22 | Marie Birgitta Källström | Other | Other | 18,752 | 40,316.80 SEK |
| 2025-04-15 | Niels Mengel | Other | Other | 92,304 | 198,453.60 SEK |
| 2025-04-15 | Peter Benson | Other | Other | 50,000 | 107,500.00 SEK |
| 2025-04-15 | Carin Linde | Other | Other | 40,328 | 86,705.20 SEK |
| 2025-04-15 | Peter Benson | Other | Other | 21,688 | 46,629.20 SEK |
| 2025-04-15 | Peter Benson | Other | Other | 20,472 | 44,014.80 SEK |
| 2025-04-15 | Julie Brogren | Other | Other | 18,000 | 38,700.00 SEK |
| 2025-04-15 | Peter Benson | Other | Other | 6,152 | 13,226.80 SEK |
| 2024-09-03 | KIBEGEON | Other | Sell | 913,545 | 150,917.63 SEK |
| 2024-09-03 | Niels Mengel | Other | Sell | 131,965 | 17,815.28 SEK |
